ORCID: https://orcid.org/0000-0002-3512-5984; Nübling, Georg; Klietz, Martin; Fietzek, Urban M.; Palleis, Carla ORCID: https://orcid.org/0000-0002-4331-8145; Bernhardt, Alexander M. ORCID: https://orcid.org/0000-0002-2572-5062; Wegner, Florian ORCID: https://orcid.org/0000-0002-9931-2666; Huber, Meret; Rogozinski, Sophia; Schneider, Luisa-Sophie; Spruth, Eike Jakob; Beyle, Aline; Vogt, Ina R.; Brandt, Moritz; Hansen, Niels; Glanz, Wenzel ORCID: https://orcid.org/0000-0002-5865-4176; Brockmann, Kathrin ORCID: https://orcid.org/0000-0002-7515-8596; Spottke, Annika; Hoffmann, Daniel C.; Peters, Oliver; Priller, Josef ORCID: https://orcid.org/0000-0001-7596-0979; Wiltfang, Jens ORCID: https://orcid.org/0000-0003-1492-5330; Düzel, Emrah ORCID: https://orcid.org/0000-0002-0139-5388; Schneider, Anja ORCID: https://orcid.org/0000-0001-9540-8700; Falkenburger, Björn; Klockgether, Thomas ORCID: https://orcid.org/0000-0001-6174-5442; Gasser, Thomas ORCID: https://orcid.org/0000-0002-1069-1146; Nuscher, Brigitte ORCID: https://orcid.org/0009-0000-4661-0742; Haass, Christian ORCID: https://orcid.org/0000-0002-4869-1627; Höglinger, Günter ORCID: https://orcid.org/0000-0001-7587-6187 und Levin, Johannes ORCID: https://orcid.org/0000-0001-5092-4306
(2024):
GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
In: Journal of Neurology, Vol. 271: pp. 6991-6999
[PDF, 1MB]
Download (1MB)
Abstract
Background : Multiple system atrophy (MSA), an atypical parkinsonian syndrome, is a rapidly progressive neurodegenerative disease with currently no established fluid biomarkers available. MSA is characterized by an oligodendroglial α-synucleinopathy, progressive neuronal cell loss and concomitant astrocytosis. Here, we investigate glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as fluid biomarkers for differential diagnosis, assessment of clinical disease severity and prediction of disease progression in MSA. Methods : GFAP and NfL levels were analyzed in plasma and CSF samples of 47 MSA patients as well as 24 Parkinson’s disease (PD) and 25 healthy controls (HC) as reference cohorts. In MSA, biomarker levels were correlated to baseline and longitudinal clinical disease severity (UMSARS scores). Results : In MSA, GFAP levels in CSF and plasma predicted baseline clinical disease severity as indicated by UMSARS scores, while NfL levels predicted clinical disease progression as indicated by longitudinal changes in UMSARS scores. Cross-sectionally, NfL levels in CSF and plasma were significantly elevated in MSA compared to both PD and HC. Receiver operating curves (ROC) indicated high diagnostic accuracy of NfL for distinguishing MSA from PD (CSF: AUC = 0.97, 95% CI 0.90–1.00; plasma: AUC = 0.90, 95% CI 0.81–1.00). Discussion : In MSA, GFAP shows promise as novel biomarker for assessing current clinical disease severity, while NfL might serve as biomarker for prediction of disease progression and differential diagnosis of MSA against PD.
| Item Type: | Journal article |
|---|---|
| Faculties: | Medicine Medicine > Munich Cluster for Systems Neurology (SyNergy) Medicine > Institute for Stroke and Dementia Research (ISD) Medicine > Medical Center of the University of Munich > Neurological Clinic and Polyclinic with Friedrich Baur Institute |
| Subjects: | 600 Technology > 610 Medicine and health |
| URN: | urn:nbn:de:bvb:19-epub-123158-6 |
| ISSN: | 0340-5354 |
| Language: | English |
| Item ID: | 123158 |
| Date Deposited: | 19. Dec 2024 07:29 |
| Last Modified: | 19. Dec 2024 07:29 |
| DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 |
Actions (login required)
- View Item
